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Abstract 
Background: Cystic fibrosis (CF) is a lethal hereditary disease characterised 
by neutrophil-dominated lung inflammation. These abundant neutrophils 
produce neutrophil elastase (NE), a destructive serine protease that has direct 
actions on extracellular matrix proteins and has a role in the host response to 
inflammation and infection.  
Objective: In this review we examine the prospect of developing novel 
therapies for CF by targeting NE. We explore the functions of NE and of 
naturally occurring and synthetic NE inhibitors. 
Conclusions: Targeting NE in CF offers therapeutic potential but optimal 













Cystic fibrosis (CF) is a lethal hereditary disorder found mainly in Europe and 
North America. It is caused by mutations of the cystic fibrosis transmembrane 
conductance regulator (CFTR) gene, a 27-exon, 250 kilobase segment of 
chromosome 7 [1-3]. This is a relatively common disorder with 1 in 20 
Caucasians being heterozygotic carriers of a mutated CFTR gene and an 
incidence of CF of 1 in 3000 live births. Hispanics, Blacks, and Asians are 
also affected, but in smaller numbers [4]. CF affects the liver, pancreas and 
intestinal tract but the major causes of morbidity and mortality are the lung 
disease [5]. This generally begins in childhood with the production of thick 
mucus, chronic airway infections, and inflammation beginning in the early 
years and leading to progressive decrement in lung function and death from 
respiratory failure [5, 6]. Other lung complications of CF include haemoptysis, 
pneumothorax, pulmonary hypertension, and cor pulmonale [5, 6].  
 
Mutations in the CFTR gene cause CFTR protein abnormalities. The 
mechanism by which this abnormal protein leads to the respiratory 
abnormalities associated with CF is not fully understood but one of the most 
striking features of the lung disease associated with CF is the sustained, 
intense neutrophil-dominated inflammation present from very early in life [7-9]. 
In the normal lung neutrophils account for approximately 1% of the 
inflammatory cell population in epithelial lining fluid (ELF) but in the CF lung 
neutrophils represent 70% of the ELF inflammatory cells [7-9]. These 
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neutrophils are ineffective in the clearance of bacteria, and play a significant 
role in the pathogenesis of the lung derangement associated with CF. The 
lung derangement is mediated in large part by neutrophil proteases and 
oxidants that overwhelm the normal anti-protease defence of the respiratory 
epithelial surface [7-11]. Neutrophil elastase (NE) is the major protease 
released by neutrophils in the CF lung and although it is not the only culprit 
causing the lung damage associated with CF, it clearly plays a major role in 
the process. NE has a number of different effects in the lung. It directly injures 
epithelial cells and interferes with the defence mechanisms of the lung by 
reducing ciliary beat frequency [12], it deranges mucus glycoprotein secretion 
[13], cleaves complement components [14, 15], and immunoglobulins [16], 
and interferes with the ability of neutrophils to kill Pseudomonas [9, 14]. More 
recently work from this laboratory has shown that NE plays a major role in the 
inactivation of elafin, a major lung anti-protease and anti-inflammatory [17] 
Furthermore NE upregulates a host of pro-inflammatory cytokines in lung 
epithelium acting through toll-like receptors [18, 19] and the epidermal growth 
factor receptor [20-22]. In addition to all of this, it now seems likely that NE 
plays a pivotal role in the upregulation of other proteases including 
metalloproteases and cysteinyl cathepsins [23]. 
 
Given this background NE represents a real target for novel therapies in the 







NE is a serine protease, a group that also includes cathepsin G and 
proteinase 3. NE is packaged in primary granules within neutrophils [24] 
(figure 1). It is coded for by a 4-kb (5 exon, 4 intron) gene on chromosome 19 
at p13.3 [25] and the sequences for the mature NE protein are included in 
exons II-V. The exon structure predicts a primary translation product of 267 
amino acid residues including a 29-residue N-terminal precursor containing 
(a) a 27-residue “pre” signal peptide followed by a “pron” di-peptide and (b) a 
20-residue C-terminal peptide. Following synthesis, the inactive precursor 
molecular form is trimmed, glycosylated with complex carbohydrates, 
transported to the Golgi, and ultimately carried to the azurophilic granules. 
The cleavage of the short N-terminal propeptide is typical for the granule-
associated serine proteases of cells of the hemopoeitic lineage where a 
cysteine proteinase, dipeptidylpeptidase I (also known as cathepsin C), 
functions as the principal posttranslational processing enzyme [26, 27]. 
In common with other serine proteases, NE is stored in a fully processed and 
activated form [28-30]. NE is a very basic protein; because of its high content 
of arginine residues, it has an isoelectric point of 9.4. 
 
The mechanism by which NE cleaves a target protein is shown in figure 2. 
The NE molecule is globular and is comprised of two complex carbohydrate 
side chains attached to Asn95 and Asn 144. The catalytic site of the NE 
molecule is an indentation of the molecule and is composed of the molecule 
and the triad His41-Asp99-Ser173, in which the -oxygen of serine becomes a 
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powerful nucleophile able to attack a suitably located carbonyl group on the 
target substrate. The bond to be cleaved must fit into the active site pocket of 
the NE held there by charge interactions and mediated by the residues 
forming the pocket. The peptide bond under attack is between two amino acid 
residues recognized by their side chains. An acyl-enzyme intermediate 
molecule is formed between serine and the carbonyl group on the target 
protein. To complete the process, the acyl-enzyme complex is hydrolysed with 
subsequent regeneration of active NE and cleavage of the protein. 
 
 
Neutrophil elastase functions (figure 3) 
NE is a powerful degrading enzyme and much research has been carried out 
to investigate this. Millimolar concentrations of NE, when released from single 
azurophilic granules of activated neutrophils, lead to evanescent quantum 
bursts of proteolytic activity before catalysis is halted by pericellular inhibitors. 
The manner in which NE degrades extracellular matrix despite the presence 
of functioning anti-protease molecules is still not fully understood. One theory 
holds that neutrophils can release oxidants which locally inactivate 
antiproteases thereby permitting NE to act on the local tissues. Work from 
Campbell’s group looked at the function of NE as regards quantum proteolysis 
[31]. Calculations from first principles indicate that approximately 67,000 
molecules of NE are stored in each azurophilic granule at a mean 
concentration of 5.33 mM, which exceeds pericellular inhibitor concentrations 
in vivo by nearly three orders of magnitude. Diffusion analysis predicts 
obligate catalytic activity (excess of local enzyme over inhibitor concentration) 
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that extends to 1.33 microns from the site of granule extrusion (7.8-fold larger 
than the mean radius of the granule), with a duration of 12.4 ms, when the 
pericellular concentration of α1AT equals that of normal plasma. In contrast, 
when polymorphonuclear cells are bathed in α1AT concentrations found in 
plasma from individuals with α1AT deficiency, the radius and duration of 
obligate catalytic activity are increased 2.5-fold and 6.2-fold, respectively. 
These simulations agree remarkably well with direct observations and provide 
a novel, nonoxidative mechanism by which quantum bursts of extracellular 
proteolytic activity occur despite proteinase inhibitors in the bathing medium. 
Titration of local enzyme-inhibitor concentration is the dominant determinant 
of the size and duration of such events. Work with α1AT deficiency serum 
samples showed that quantum proteolytic events are abnormally large and 
prolonged in α1AT deficiency, leading directly to an increased risk of tissue 
injury in the immediate vicinity of activated neutrophils [32]. This may give an 
insight into the destructive activity of NE in patients with CF, where the 
problem of protease antiprotease balance is not one of inhibitor deficiency but 
rather enzyme excess. 
 
The term neutrophil elastase is partly a misnomer as not only does NE 
degrade elastin but also degrades almost all extracellular matrix and key 
plasma proteins. NE has broad substrate specificity and is capable of 
degrading a wide range of extracellular matrix proteins including elastin, 
collagen (types I-IV), fibronectin, laminin, and proteolglycans [33-37]. Other 
extracellular matrix proteins degraded include platelet IIb/IIIa receptor, 
complement receptor, thrombomodulin, lung surfactant, and cadherins [38-
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42]. In addition, NE can cleave coagulation factors (fibrinogen and factors V, 
VII, XII, and XIII), plasminogen, IgG, IgA, and IgM, complement factors C3 
and C5, complement receptors, and gp120, the coat protein of the human 
immunodeficiency virus [43-45]. It may also cleave other proteases found 
within neutrophil granules [46] and also other protease inhibitors [47, 48] 
leading to their activation or their loss of function. (Table: 1) 
 
NE has also been shown to upregulate pro-inflammatory cytokines. For 
example, NE upregulates IL8 expression and secretion from bronchial 
epithelial cells by signalling through toll-like receptor 4 (TLR4) [49, 18]. NE-
induced upregulation of IL8 expression in human bronchial epithelial cells 
depends on the proteolytic activity of NE, as inhibition with the serine-
protease inhibitor phenylmethylsulphonyl fluoride (PMSF) abolishes this 
specific activation. Similarly, Tsujimoto et al. showed that pre-treatment with 
an inhibitor of NE decreased lipopolysaccharide (LPS)-induced CXCL2 
production by the human macrophage cell line RAW 264.7 in a dose-
dependent manner [50]. NE also upregulates leukotriene B4 (LTB4) secretion 
from macrophages [51]. 
 
NE contributes to chronic inflammatory airway diseases by inducing mucin 
production in airway epithelial cells [20]. The exact mechanism by which NE 
mediates this effect is unclear but has been shown to involve activation of 
protein kinase C (PKC) and production of reactive oxygen species (ROS). 
ROS in turn activate TNF-a (tumour necrosis factor-a)-converting enzyme 
(TACE), leading to TACE-dependent release of soluble transforming growth 
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factor-α (TGFα) and TGFα stimulation of epidermal-growth-factor receptor 
(EGFR), which induces the production of mucin [21]. However other 
metalloproteases may also be involved in these processes including meprin 
[22]. 
 
NE and other serine proteases have also been shown to have an effect at the 
cell surface. NE can cleave cell-surface adhesion molecules, such as 
intercellular adhesion molecule 1 (ICAM1), vascular cell-adhesion molecule 1 
(VCAM1) and epithelial (E)-cadherin [52-54]. As cell migration involves a 
series of attachment and detachment events, the shedding of adhesion 
molecules from the cell surface by proteases might provide a mechanism to 
regulate and terminate cell-cell or cell-extracellular matrix interactions. It is 
postulated that serine proteases are involved in activation of the pro-form of 
tumour necrosis factor and interleukin-1β [55, 56] but interestingly NE and 
cathepsin G both degrade mature TNF [57] and all three serine proteases can 
inactivate IL-6 [58].  
 
Although much research has centred on the destructive nature of NE in 
degrading a multitude of proteins, recent evidence has emphasised the role of 
NE in the host immune response to infection. For example, while neutrophils 
may migrate normally to sites of infection in the absence of NE, NE is required 
for maximal intracellular killing of Gram-negative bacteria by neutrophils [59].  
In addition to the intracellular activities of the neutrophil serine proteases, it 
has been shown that serine proteases released from neutrophils form 
neutrophil extracellular traps (NETs) with chromatin and that NETs bind 
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Gram-positive and Gram-negative bacteria [60]. These NETs allow 
neutrophils to deliver high concentrations of serine proteases that degrade 
virulence factors and kill bacteria extracellularly. A proportion of NE remains 
bound to the cell surface of neutrophils when azurophilic granules fuse with 
the plasma membrane during exocytosis. The concentrated expression of the 
neutrophil serine proteases on the outer surface of the plasma membrane [61, 
62] allows neutrophils to modulate the inflammatory response. In support of 
this idea, inhibition of neutrophil serine proteases has been shown to reduce 
neutrophil infiltration and neutrophil-mediated injury in various modes of 
inflammation, including ischaemia and reperfusion injury, endotoxin-induced 
acute lung injury and collagen-induced arthritis [63-65].  
 
These data show that there is a fine balance between the physiologic and 
deleterious effects of NE. When this balance is disturbed, as in the case of 
α1AT deficiency where there is too little NE-inhibition or in CF where there is 
dysregulated NE release, lung damage results. While it is generally accepted 
that large quantities of active extracellular NE in the lung is potentially 
deleterious and should be inhibited to prevent further lung damage, 
intracellular and locally expressed NE may be important for host defence and 
should not be inhibited. This has important implications for the type of 
inhibitors which should be used. 
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Anti-NE Defences of the lung 
In normal lungs the anti-NE defences include, 1AT, secretory leukoprotease 
inhibitor (SLPI) and elafin. Individuals with CF have normal serum and ELF 
levels of all three [7, 8]. α1AT is produced in the liver and from there circulates 
to the lung where it provides the major anti-NE protection to the lower 
respiratory tract [66]. The importance of α1AT and NE in lung protection and 
destruction respectively is illustrated by α1AT deficiency, a hereditary disorder 
associated with polymerisation of the mutant α1AT in the liver, decreased 
secretion of α1AT into the circulation and a markedly diminished anti-NE 
protective defence in the lung [67]. This condition is associated with 
premature aggressive emphysema, a condition which is aggravated greatly by 
the effects of cigarette smoke in oxidising and further inactivating α1AT 
leading to an unopposed action of NE [68].  
 
The roles of SLPI and elafin in protecting the lung from NE are less well 
defined. Both of these molecules are produced locally by epithelial cells and it 
has been suggested that SLPI may function as an anti-NE molecule mostly in 
the upper airways. More recently research has focussed on the anti-
inflammatory effects of these molecules and by extension on the deleterious 
effects of NE in inhibiting these activities. SLPI and elafin have been shown to 
inhibit nuclear factor-kappa B (NFκB) activation, and IL-8 and monocyte 
chemoattractant protein-1 (MCP-1) production by epithelial cells and 
monocytes. However, whereas elafin is inactivated by NE in CF ELF [17], 
SLPI is relatively immune to the direct proteolytic effects of NE but is readily 
proteolysed by cysteinyl cathepsins [69] and metalloproteases both of which 
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are upregulated by NE [23]. Cysteinyl proteases also cleave and inactivate 
defensins [70] and lactoferrin, two locally produced anti-microbials with direct 
relevance to CF as defensins are key mediators of Pseudomonas killing and 
lactoferrin has a major role in inhibiting biofilm formation [71]. 
 
Individuals with CF have normal to high serum and ELF levels of all three of 
the major anti-NE compounds [7, 8]. However, α1AT, elafin and SLPI in CF 
ELF are completely inactive, being complexed with or cleaved by NE and 
other proteases or rendered impotent by oxidants produced by inflammatory 
cells [7, 8]. The presence of large amount of neutrophils on the respiratory 
epithelial surface, brought there by abundant neutrophil chemoattractants 
(including IL8, Leukotriene B4, C5A) and α1AT-NE complexes results in large 
quantities of unopposed NE on the respiratory epithelial surface of individuals 
with CF. The levels of NE in CF ELF vary markedly, but can be as high as 100 
µM. These levels correlate inversely with pulmonary function in individuals 
with CF. This illustrates one of the enduring difficulties in dealing with the 
neutrophil dominated inflammation in CF, namely the recurring cycle of NE 
induced inflammation. NE upregulates IL8 from epithelial cells and LTB4 from 
macrophages creating a gradient of neutrophil chemoattraction bringing more 
neutrophils onto the epithelial surface where they are readily activated to 
produce more NE by cytokines such as IL8 and TNF. Adding to this 
complexity the neutrophil in individuals with CF is also intrinsically abnormal 
and secretes more NE than non-CF neutrophils in response to IL8, TNF and 
LPS all of which are found in abundance in the CF lung [72].  
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Targeting neutrophil elastase in cystic fibrosis  
(figure 4) 
Strategies to prevent NE-mediated lung derangement in CF are based on the 
theory of increasing the level of antiproteases available to inhibit NE or 
lowering the burden of NE in the lung. In CF, the levels of NE in ELF vary 
dramatically from individual to individual, and even in the same individual over 
time, so that it is difficult to determine the level of augmentation required. 
Approaches to augment the anti-NE defenses of the lung in CF include (a) 
augmentation with plasma purified α1AT, (b) augmentation using recombinant 
antiproteases or other naturally occurring antiproteases, (c) use of chemical 
antiproteases, and (d) gene therapy. The inhibition of NE in CF, should not 
only directly protect the lung but also lower the neutrophil burden, and 
enhance host defence by protecting complement, complement receptors, and 
locally produced antimicrobials and antiinflammatories such as SLPI, elafin, 
defensins and lactoferrin.  
 
Augmentation with purified plasma α1AT 
Much of the work on intravenous administration of purified α1AT has been 
carried out in the context of α1AT deficiency. The seminal paper by Wewers 
et al [73] showed that once weekly intravenous administrations of plasma 
purified α1AT led to levels of serum α1AT above a putative protective 
threshold of 11M throughout the duration of therapy. This serum data was 
complemented by data showing that ELF levels of α1AT and anti-NE capacity 
were also raised by this intravenous administration to the normal α1AT ELF 
levels. As a next step from this it was deemed logical that the enormous NE 
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burden on the epithelial surface in CF could be inhibited by intravenous 
augmentation with α1AT [8]. Purified plasma α1AT was administered at 
dosages ranging from 60 to 120 mg/kg once weekly. However, only dosages 
in the 120-mg/kg range were able to elevate α1AT levels sufficiently to inhibit 
the NE burden in these individuals. Unfortunately, the inhibition was brief, with 
reappearance of active NE on the respiratory epithelial surface within 1 week 
after administration, suggesting that this approach, although effective in the 
short term was not feasible as it would require frequent intravenous 
administration of large doses of α1AT to have the desired effect. Recombinant 
forms of α1AT have not been effective when administered intravenously as 
those raised in yeast are non-glycosylated with a resultant very short plasma 
half life while those produced from transgenic animals had different 
glycosylation to plasma purified α1AT also leading to alterations in half life. 
[74-76]. Animal studies evaluating intravenous infusion of SLPI showed an 
unacceptably high level of proteinuria [77]. Slowing the infusion decreased the 
levels of protein in urine but this approach has not been pursued. Because of 
these results and because CF is mainly a bronchial disease it was decided 




Aerosol Augmentation with α1AT 
This was first attempted in 1991 [66]. 1.5-3mg/kg of purified plasma α1AT was 
administered twice daily to individuals with CF. This resulted in inhibition of 
NE on the respiratory epithelial surface and re-establishment of the ELF anti-
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NE capacity, but only if the levels of α1AT in ELF exceeded 8µM. However 
this study also highlighted another potentially useful effect of inhibiting NE in 
CF. After suppression of the NE burden in CF ELF with aerosolized 1AT, the 
ability of CF ELF to inhibit neutrophil killing of Pseudomonas was abolished. 
This was due in part to the inhibition of NE in CF ELF preventing it from 
cleaving complement receptors on the neutrophils. Furthermore suppression 
of NE in CF is associated with decreased IL-8 in CF ELF and decreased 
neutrophil numbers on the epithelial surface [8]. These findings have been 
replicated by others. Berger et al showed that aerosolised plasma purified 
α1AT inhibited NE in ELF and that this inhibition was related to the doses of 
α1AT delivered [78]. They did not show a significant effect on IL-8 or 
neutrophil count. Interestingly there was no correlation between sputum and 
ELF NE levels. A recent study from Griese et al, examined the effect of 4 
weeks of plasma purified α1AT inhalation on lung function, protease-
antiprotease balance and airway inflammation in CF patients [79]. They found 
that this therapy increased α1AT levels and decreased the levels of NE 
activity, neutrophils, pro-inflammatory cytokines and the numbers of P. 
aeruginosa. However, as might be expected, given the short duration of this 
study, there was no effect on lung function. This study mainly evaluated 
sputum based parameters and speculated on the reasons for some of the 
differences noted between parameters measured in sputum and ELF. 
 
Secretory Leukoprotease Inhibitor 
Another candidate as an anti-NE molecule for CF is recombinant SLPI, a 12-
kDa-nonglycosylated single-chain polypeptide identical to the naturally 
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occurring SLPI [80-83]. Advantages of SLPI as a potential therapeutic option 
are that it is acid stable which may allow it to retain function in the acidic pH of 
the metabolically active neutrophils [84, 85], its isoelectric point of 9 is close to 
that of NE which may allow it to track and bind to tissue sites favoured by NE 
[86, 87], its relative imperviousness to degradation by NE and its possible 
enhanced antioxidant function by increasing glutathione levels in the local 
milieu [88]. Despite the postulated advantages, delivery of SLPI to the lungs 
has proven unimpressive [89]. Aerosolization of 100 mg of recombinant SLPI 
twice daily to individuals with CF was associated with inhibition of NE on the 
respiratory epithelial surface, as well as decreases in the levels of IL-8 and 
neutrophil numbers in ELF [8]. However, relatively more recombinant SLPI 
than α1AT is required to suppress ELF NE levels in individuals with CF. 
Furthermore, recombinant SLPI does not accumulate on the respiratory 
epithelial surface either in controls or in individuals with CF, and most of the 
anti-NE effects are gone within 12 hours of administration. The reasons for 
this are not fully elucidated but may be due to compartmentalization of SLPI to 
the epithelial surface, absorption of recombinant SLPI into epithelial cells and 
macrophages, and/or binding of recombinant SLPI to molecules in the 
interstitium after passing through the epithelium [89, 7]. Also more recently it 
has been shown that SLPI is easily degraded by cysteinyl cathepsins which 
are present in very high quantities in CF ELF [69]. Thus, although SLPI has 
several theoretical advantages to augment anti-NE in the lung, the successful 




Other naturally occurring antiproteases 
Elafin is a cationic protease inhibitor of human NE, proteinase 3, and porcine 
pancreatic elastase. It was previously shown that elafin and its precursor 
trappin-2 retain the ability to inhibit neutrophil serine proteinases when they 
are covalently bound to extracellular matrix proteins by tissue 
transglutaminase [90]. More recent work in U937 cells showed that elafin 
inhibits LPS-induced production of MCP-1 by preventing the LPS-induced 
activation of AP-1 and NFκB [91]. This anti-inflammatory effect appears to be 
dependent upon an effect of elafin on the ubiquitin-proteasome pathway. Due 
to the selective expression of elafin at mucosal surfaces, as well as in alveolar 
macrophages, monocytes and neutrophils, the ability of elafin to inhibit LPS 
signalling may be important in CF and may represent another therapeutic 
option. Unfortunately in areas of NE excess elafin is degraded and inactivated 
by the NE [17].  
 
Human monocyte/neutrophil elastase inhibitor (MNEI), a 42-kDa serine 
protease inhibitor (serpin) protein, is an effective inhibitor of NE, cathepsin G, 
and proteinase-3 [92]. Recombinant MNEI has been given daily by aerosol to 
rats, previously infected with P. aeruginosa. The treatment with MNEI 
significantly decreased the extent of inflammatory injury and improved 
clearance of bacteria from the infected rat lungs. Similar results have been 
obtained for aerosolized α1AT in a rat model of CF lung inflammation [93]. 
This suggests another potential parameter to evaluate the efficacy of anti-
protease therapy in CF. 
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Other naturally occurring antiproteases include eglin-c, a single-chain 
polypeptide purified from the medicinal leech Hirudo medicinalis. 
Recombinant eglin-c inhibits NE and cathepsin G, as well as several other 
proteases, and intratracheal instillation of eglin-c has been shown to attenuate 
the severity of NE induced emphysema in hamsters [94-96]. However, as 
might be expected of a protein from a nonhuman source, eglin-c is allergenic 
to humans and cannot be used clinically in its present form.  
 
NE is markedly inhibited by cis-unsaturated fatty acids, such as oleic acid. A 
family of serine protease inhibitors has been identified in the seeds of squash 
(Curcurbita maxima), several of which might be potentially useful [97]. A 
number of NE inhibitors have been isolated from microorganisms, including 
elasnin, elasninal, chymostatin, leupeptin, valinal, and antipain [98]. As for 
eglin-c the clinical application of these substances is limited by the possibility 
of immune reactions.  
 
Three naturally occurring dithiol reducing systems have been examined for 
their effects on elastase activity: 1) Escherichia coli thioredoxin (trx) system, 
2) recombinant human thioredoxin (trx) system, and 3) dihydrolipoic acid 
(DHLA) [99]. The ability of Trx and DHLA to limit elastase activity combined 
with their mucolytic effects makes these compounds potential therapies for 
CF. 
 
More recently work has been done on greglin, a novel locust serine protease 
inhibitor with a high affinity for NE [100]. This is a fast acting and tight binding 
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inhibitor of human NE, which also binds neutrophil cathepsin G, pancreatic 
elastase and chymotrypsin with lower affinity. This has been shown to inhibit 
NE activity in sputum supernatants from CF patients.  
 
Low-molecular weight inhibitors of NE 
A number of synthetic NE inhibitors have been developed as potential 
therapeutic agents for α1AT deficiency.  These include irreversible inhibitors 
such as the peptide chloromethyl ketones [101] and reversible inhibitors such 
as peptide boronic acids [102], peptide aldehydes [103], substituted tripeptide 
ketones [104], or β-lactams that have been modified to inhibit NE [105]. One 
of the problems with the low-molecular-weight reversible inhibitors is that they 
can release NE, allowing it to destroy tissue.  Although the irreversible 
inhibitors such as chloromethyl ketone have been shown to function 
effectively in vivo in hamsters to reduce many of the effects of intratracheally 
administered NE, the toxicity of chloromethyl ketones prevents clinical use. 
 
β-lactam-based compounds have been identified as specific potent inhibitors 
of NE [105]. The fact that these molecules clear rapidly from circulation 
suggests that they may be limited to aerosol therapy. From kinetic data, 
Gorrini et al concluded that the macrolide antibiotic erythromycin acts as an 
alternate substrate NE inhibitor and that flurythromycin acts as an inactivator 
[106]. L-658,758, a cephalosporin-based drug, is another antibiotic which has 
inhibitory effects on NE, proteinase-3 and CF sputum soluble elastase [107]. 
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Small molecules can gain access to tissue sites inaccessible to larger 
molecules. This is a potential advantage and a potential disadvantage. While 
these inhibitors may prevent NE from attacking connective tissue in confined 
areas such as beneath the surface of neutrophils they may also inhibit 
proteases at sites where they perform a physiological function, such as 
intracellularly or in their role as facilitators of cell movement through tissue 
[108].  
 
Initial work in vivo and in vitro, in rats, on a new, rapidly acting, potent and 
specific NE inhibitor, EPI-HNE-4 demonstrated an effective inhibition in vitro 
of the high levels of active NE present in a medium as complex as sputum 
from children with CF by almost complete block of N-formyl-methionine-
leucine-phenylalanine-induced migration of purified human neutrophils across 
a Matrigel basement membrane [109]. Intratracheal administration of EPI-
HNE-4 and intravenous administration brought about inhibition of NE and of 
neutrophil influx in the rat. This suggested a potential for associated aerosol 
and systemic administration of EPI-HNE-4 in the treatment of CF. Further 
work on this agent showed that it can be nebulised efficiently without 
decrease in its activity and that mixing the inhibitor with (99m)Tc human 
serum albumin tracer should allow quantification of its deposition in CF 
patients [110]. EPI-HNE4 is also resistant to hydrolysis by neutrophils in 
inflammatory lung secretions, including metalloproteases (MMPs) 7, 8 and 9, 
and the elastase-related protease 3 and cathepsin G [111]. While these initial 
results are encouraging this agent is still some distance from demonstration of 




Whilst various viral vectors continue to be evaluated as a method of transfer 
of CFTR in CF [112], the delivery of the α1AT cDNA via different vectors to 
increase the antiprotease activity in CF is another possibility. Plasmid cationic 
liposome mediated α1AT gene transfer to a CF bronchial epithelial cell line 
was first performed in 1996 [113]. This protected the cells from NE damage. 
To date there have been a number of animal studies evaluating the potential 
of transferring the α1AT cDNA to muscle liver and lung in the hope of 
producing therapeutic levels of α1AT in plasma. These studies used an 
adeno-associated virus vector delivery system and achieved significant levels 
of α1AT over prolonged periods of time, up to months, and a subsequent 
phase I trail revealed no serious vector-related adverse events [114]. 
However to date no human trials have been forthcoming probably because of 
the availability of an alternative in plasma purified augmentation therapy.  
 
Delivering an agent to the lung 
A further hurdle to the targeting of NE to achieve therapeutic potential in CF is 
the delivery of an agent to the lung. This is a problem that has been faced in 
attempting to optimise delivery of antibiotics to the lung in CF [115]. There are 
many advantages to aerosol delivery as opposed to systemic administration; 
the agent is delivered directly to the site of action, there is less systemic 
toxicity, it can be self administered and higher concentrations are available at 
the site of the lung disease. Drawbacks of this approach include difficulties in 
determining pharmacokinetics and sampling of ELF to quantify inhibitory 
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effects. Nebulisation can affect drug activity and, depending on whether 
administration is preferable in the upper or lower airways, optimum particle 
size and device type must be evaluated. Factors such as biofilm, the physical 
and chemical composition of mucus and the degree of parenchymal 
destruction and bronchiectasis in CF patients can significantly alter drug 
distribution and bioavailability. In the case of antibiotics two classes of 
antagonistic sputum components have been identified. They are small 
molecules which physically decrease antibiotic penetration into bacteria, and 
large glycoprotein molecules, which bind and sequester aminoglycosides 
[116]. Sputum glycoproteins such as mucin and DNA in CF patients can bind 
polycations such as aminoglycosides. Glycoprotein content varies amongst 
CF patients but can bind approximately 90% of the drug. Soluble sputum 
components such as monovalent and divalent cations, vary little among 
patients [117].  Divalent ions bind approximately 5% of aminoglycoside given 
and DNA binds approximately another 2%.  
 
The desired properties of an ideal aerosolised therapeutic agent in CF 
patients are many. Particle sizes ranging from 1 to 5 μm appear to be optimal 
for reproducible drug delivery to the airways [118, 119]. The agent should be 
sterile and nonpyrogenic as allergic reactions to impure recombinant or 
plasma-purified preparations may occur [120]. To aid in patient compliance it 
should be reasonably palatable. To allow for the varying conditions that it will 
encounter in the lungs of CF patients which will alter the delivered 
concentration it should have a wide margin of dosage safety. The ideal 
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There is no doubt that the lung disease in CF is mediated, at least in part, by 
the effects of NE. These effects are myriad, directly acting to degrade 
extracellular matrices, impairing host defence, increasing mucin and cytokine 
production and upregulating other potentially deleterious proteases in the 
lung. Whereas normally NE has an important role itself in host defence, in CF 
the secretion of NE is dysregulated so that there is an excess of extracellular 
NE and the normal anti-NE protective mechanisms are ineffective. In this 
context it makes sense that extracellular active NE in the lung epithelial 
surface should be inhibited. Given the newly discovered anti-inflammatory 
effects of many anti-NE molecules it becomes more important than ever to try 
to restore the normal NE/anti-NE balance in the CF lung. At the present time 
most experience is with the natural inhibitors of NE such as plasma purified 
α1AT but other recombinant and synthetic molecules are being studied. The 
major problems with plasma-purified α1AT have been fears of blood borne 
infections and lack of supply. Recombinant preparations also have potential 
problems; some cannot be given by intravenous route and those given by 
aerosol need to be rigorously tested for impurities. The future is likely to see 
customised combinatorial therapies designed specifically for CF patients that 
take into account bacterial colonisation status, NE activity, and mucus, DNA 
and glycoprotein levels.  Aerosolisation is the most promising route of 
administration and aerosolisation of anti-NE molecules may be combined with 
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other aerosolisation therapeutics. Problems posed by drug binding and 
sequestration, charge factors and accessibility to the airway epithelium pose 
major challenges and advances in delivery technologies are needed.  
 
The effects of successful anti-NE therapy will need to be evaluated at a 
variety of levels. Firstly the therapies must be shown to inhibit NE and in doing 
so decrease other pro-inflammatory cytokines and proteases. Conceivably 
this could lead to decreased bacterial load which could serve as a useful 
surrogate measure of clinical efficacy both in short term and long term 
studies. The previous gold standard in all lung studies of an improvement or 
decreased deterioration in pulmonary function will not be achievable in short 
term studies and may best be reserved for the more definitive stage 3 studies 
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